ABSTRACT Epidemiological problems arising from the absence of an agreed definition of asthma have led to the use of bronchial reactivity tests in community surveys of asthma prevalence. Since only a minority of the general population will develop bronchoconstriction in response to the dose of histamine considered acceptable for use in the community it is important to make maximum use of the data available. Several methods for summarising the information in the dose-response curve obtained from a histamine challenge test have been compared. A standardised histamine challenge test was administered to 797 subjects selected from two communities, and a repeat test to 106 subjects. The test was well accepted. For most subjects FEV1 rose initially after administration of histamine (median rise 100 ml), so maximum FEV1 was used as the baseline from which the 20% fall to achieve a PD20 was calculated. In order to use all the data rather than just two points on the FEVY-log dose graph, PD20 was estimated by means of curve fitting, and the values were compared with PD20 from linear interpolation. An exponential curve was found to fit the data well. Extrapolation from the maximum dose of 4 tmol up to 8 umol was allowed in the estimation of PD20 by both methods. The curve fitting method gave slightly more reproducible PD20 values than did linear interpolation, and also gave more estimates in the range 0-03-8 4umol. The repeatability of PD20 compared well with that of asthmatic subjects tested in a clinical environment. Curve fitting has an advantage over linear interpolation in large community studies, for which analysis of data by computer is essential.
Introduction
Most patients with asthma show bronchial hyperreactivity to a variety of non-allergenic stimuli,' although the precise relationship between reactivity and asthma is still debated. In general, hyperreactivity is related to the severity of asthma, as judged by symptoms, requirement for treatment,3 and diurnal variation in peak expiratory flow. 4 Various guidelines have recently been suggested for the standardisation of bronchial challenge tests. 5 6 The epidemiological problems arising from the absence of any agreed definition of asthma have led to interest in the possibility of using tests of bronchial reactivity in community surveys. In this situation the test needs to be quick and simple and be acceptable to the general population, and to give reproducible results under field conditions. It is essential to have a standardised protocol to be used for all subjects. Yan et al6 have developed a method for this purpose, giving increasing concentrations of histamine from hand held deVilbiss nebulisers and measuring the response as the dose of histamine estimated by interpolation to cause a 20% fall (PD20) in one second forced expiratory volume (FEV1). In a pilot study Britton et al7 showed Yan's method to be quicker and at least as reproducible as two alternative tests, and this was therefore the method chosen for the community survey.
Measurement of bronchial reactivity in epidemiological studies is subject to certain restraints. Few of the population will have had any previous experience of forced expiratory manoeuvres. Since the general population may be less tolerant of side effects than subjects in the laboratory, the maximum dose of histamine that can be given is lower, and a smaller proportion of subjects will have a PD20 that can be esti-46 mated. Hence it is important to obtain the maximum information from the data that are obtained.
In the main study Yan's method of histamine challenge was used to measure PD20 in 797 subjects as part of a community survey of asthma prevalence in two areas of southern England.8 Repeat studies were performed in 106 subjects 1-14 days after the first test. In the study reported in this paper we set out to establish the best way to analyse histamine challenge doseresponse data obtained in an epidemiological setting by determining: (1) the proportion of subjects for whom a PD20 value was obtained by fitting doseresponse curves compared with the use of linear interpolation; (2) the repeatability of PD20 values for the two methods; (3) whether PD20 should be estimated as a 20% fall from the post-saline FEV, or the maximum FEV,.
PD,o was estimated and assessed in the same way as PD20. The fact that more subjects would have a PD,o than a PD20 value of <8 pmol could favour the use of PDio in a community survey if the results are as repeatable.
Methods

SUBJECTS
A questionnaire about symptoms of asthma was administered to all subjects aged 18-64 years in two villages in Hampshire and a market town in Dorset as part of a study of asthma prevalence. After completion of the questionnaire 1325 subjects were asked to attend for a histamine challenge test at their general practitioner's surgery or health clinic. The subjects consisted of two groups, a 20% random sample (855) of the 4277 subjects aged 18-64 years who returned a completed questionnaire and all remaining subjects (470) who answered "Yes" to the question "Have you had wheezing or whistling in your chest at any time in the last 12 months?" In this paper no distinction is made between the two groups of subjects; the prevalence of hyperreactivity and its relation to smoking history and skin sensitivity as estimated from the random sample has been reported8 and the relation of hyperreactivity to associated symptoms will be reported later.
Subjects who had taken theophyllines or antihistamines in the previous 24 hours or a bronchodilator in the last six hours were asked to return later after omitting this treatment. Ethical approval was obtained from the local ethical committees and all subjects had the test explained and signed a consent form before the test was carried out.
A total of 170 subjects were invited to return for a second histamine challenge test. These consisted of a 10% random sample of all subjects in one area and in addition all subjects whose FEV1 had fallen by 20% Chinn, Britton, Burney, Tattersfield, Papacosta in the initial test in both areas, plus a few subjects whose fall in FEV, approached 20%. The decision to adminster the second test by the same or a different person was taken at random.
MEASUREMENTS
Height was measured and predicted FEV1 calculated as recommended by Cotes etal.9 FEV, and forced vital capacity were measured with a dry spirometer (Vitalograph, Buckingham, England). Initial FEV1 was recorded as the maximum of three consecutive measurements that agreed to within 5%. Subjects whose initial FEV1 was less than 60% of the predicted value were not challenged with histamine.
Other details of the histamine challenge test were as described by Yan et al,6 with doubling doses of from 0 03 to 4 pmol administered to subjects with a history of wheezing or whose post-saline FEV1 was less than 90% predicted. All other subjects were given 0-06 umol histamine followed by quadrupling doses of histamine until their FEV1 had fallen by at least 10%, when the challenge regimen was changed to the slower schedule. The test was stopped when the FEV1 had fallen by 20% or more from the post-saline value or the 4 0 umol dose had been given, or at the subject's request.
ESTIMATION OF PD20
PD20 FEV1 was estimated by linear interpolation on the basis of data from the last two doses administered,'0 with extrapolation to one doubling dose (8 umol) beyond the maximum administered, following Cockcroft et al. " PD20 was estimated by using all the available data and fitting the exponential curve log ,(c -y) = a + bx,
where y is FEVY, x is log,0 (dose), c represents mean FEV1 before it is affected by histamine, b is a "slope" parameter, and a is a curve position parameter. Since Woolcock et al12 fitted a logistic curve, we also fitted loge (c -y)/y = a + bx. (Curve 2) Extrapolation to a dose of 8 pmol was allowed for both curves as with the linear interpolation method.
Curves were fitted provided that two or more doses of histamine were administered-that is, they were fitted to all sets of data for which PD20 values were obtained by linear interpolation. When only two doses of histamine were given the post-saline FEV1 was used as the estimate of c. Details are given in the appendix.
Most subjects showed a small increase in FEV1 after the low dose of histamine, so we also calculated the estimates described above as the dose producing a 20% fall from maximum FEV1. Linear interpolation uses the doses either side of the estimate. Occasionally both the last two doses administered produced a Estimation and repeatability of the response to inhaled histamine in a community survey greater than a 20% fall from maximum FEV1 and in this case the two appropriate earlier doses were used for the estimate. This corresponds to the procedure that would be followed if the test were terminated when a 20% fall from maximum FEV1 was reached. An example of each curve fitted to data for one subject is shown in figure 1 , for whom the second administered dose of histamine produced a 20% fall from FEV1 maximum.
The methods of estimating PD20 were compared according to the number of subjects who achieved a PD20 and the repeatability of the measurements. PD10 was estimated, by linear interpolation and from the same curves, in a similar way to PD20.
REPEATABILITY
The mean and standard deviation of the difference between the estimates of PD20 for repeat tests were calculated for the subjects tested twice. Repeatability was also calculated for PD1O, post-saline FEV1, and maximum FEV1. The within subject standard deviation was calculated by dividing the standard deviation of the difference of two repeat estimates by, the square root of 2.13 A dimensionless measure of repeatability, intraclass correlation coefficient,14 was also calculated.
Results
Of 1325 subjects invited to undergo a histamine challenge test, 834 (63%) agreed. Thirty seven subjects were not given histamine, four owing to difficulty in complying with instructions and 33 because the initial or post-saline FEV1 was less than 60% predicted. Thus 797 subjects were given at least one dose of histamine at the first test, including four subjects with an initial FEV1 less than 60% predicted who were given histamine in error; of these, 512 (64-2%) were randomly selected.
Most subjects (74.4%) increased their FEV1 after the post-saline measurement, 83 (10-4%) having their maximum recorded FEV1 after the final 4Mmol dose of histamine. The increase in FEV1 over the postsaline FEV1 ranged up to 0 9 litre in absolute terms (a 30% increase), although the median increase was only 100 ml.
Four subjects were given just one dose of histamine, of whom three had a 20% fall in FEV1 after that dose and so did not have a PD20 that could be estimated. Each method of estimation of PD20 was applied to the data for the remaining 793 subjects. The residual standard deviation about the curves was less than 0-21 for 88-1% of subjects for curve I and 86-0% for curve 2; the mean residual standard deviation was 0151 for each curve. The larger residual standard deviations were found to be due to random variation in the FEV1 rather than systematic deviations from the fitted curves. This is illustrated in the example in figure 1 , where the residual standard deviations about the curves were 0-23 and 0-21 1. 1 . Figure 2 shows the relation between curve 1 PD20 for the second test to that for the first, on the basis of fall from maximum FEV1. The choice of baseline had little influence on the repeatability of the estimated PD20.
The post-saline FEV1 was slightly less repeatable than maximum FEV1. group.bmj.com on April 13, 2017 -Published by http://thorax.bmj.com/ Downloaded from Estimation and repeatability of the response to inhaled histamine in a community survey4 maximum as baseline, compared with that of PD20 in the same 90 subjects, whose data are given in column 2 of table 2. The intraclass correlation coefficient was less than that for PD20 in these subjects. Estimates of repeatability of PD10 from curve 2, and estimates based on post-saline FEVI, were similar. PD10 estimated by linear interpolation was less repeatable, the difference in repeatability being similar to that of PD20 (data available but not shown).
Repeatability was affected to a small extent by differences in time of day of measurement, the time between tests (range 1-14 days), and the person performing the test. Data were available for the 27 subjects retested one day later, at the same time of day to within one hour, and by the same tester. If we excluded two subjects with a PD20 greater than 8 umol on both occasions, the within subject standard deviation of curve 1 PD20 was reduced from 0-27 (table 3) 
Discussion
Studies on asthma prevalence have been greatly hampered by the absence of an agreed definition of asthma. Measurement of bronchial responsiveness provides an objective test, and since it is an important marker of asthma there has been interest recently in exploring the role of bronchial reactivity measurement in the assessment of asthma prevalence in the community.
Measurement of bronchial reactivity in large surveys poses different problems from measurements in the laboratory. The incidence of side effects considered acceptable in a community may be lower than for subjects in the laboratory, so a lower maximum dose of histamine has to be given. We found in a pilot study that the test described by Yan et al6 was feasible in inexperienced subjects and that 4 pmol histamine was the highest dose that was generally well tolerated. With this low maximum dose of histamine fewer subjects will develop bronchoconstriction, so it is important to estimate the response by a method that makes maximum use of the information available. PD20 values have usually been obtained by linear interpolation between the response to the last two doses of histamine, with extrapolation up to one further doubling concentration of histamine by some workers. 4 11 This technique is simple and gives an immediate answer. Fitting a curve to the data is more complicated but, when the data are of necessity analysed by computer, curve fitting is no more difficult than linear interpolation. Since we needed to analyse a large number of histamine dose-response curves we decided to compare the linear interpolation method with two curve fitting models, extrapolating up to one doubling dose (8 imol) for each method to increase the number of estimates. We did not include in this comparison estimates of PD20 if only one dose of histamine was given, as the published method of estimation requires linear interpolation between postsaline FEV1 and post-histamine FEV1 at the first dose on a linear scale10 and is inappropriate when linear 50 interpolation is otherwise carried out on a log-dose scale (post-saline "dose" = 0, and log (0) = -oo).
We looked at two curves, both of which are described by the minimum three parameters, upper asymptote, slope, and position. Both curves appear to be preferable to the quadratic equation recommended by Neijen's1' which is less flexible in shape and has no slope parameter. Curve 1 was the simplest such curve. Curve 2 was chosen because Woolcock et al12 had fitted a logistic curve to their data. The repeatability of PD20 values from curve 2 was less good than that of values from curve 1.
On the basis of fall from maximum FEVY, a PD20 value was obtained in 173 subjects by the linear interpolation method. Curve fitting increased the number of subjects with an estimated PD20 value by 35 and 28 subjects respectively for curves 1 and 2. The lower number from linear interpolation occurred in part because an extrapolated value was obtained only if the FEV1 after the final dose was less than the previous FEV1, whereas curve fitting provided an estimate whether or not this was the case. In the subjects tested twice there were correspondingly more estimates by curve fitting than by linear interpolation, which led to more subjects with one or both estimates less than 8 Lmol. The repeatability of PD20 values obtained by fitting curve 1 was better than that of values obtained by linear interpolation, as shown by column 2 of table 2. Column 3, which contains results only for subjects with all estimates less than 8 imol, apparently shows greater repeatability for linear interpolation and curve 2 estimates than does column 2 and lower repeatability for curve I estimates. This is because some of the subjects who are included in column 2 but not in column 3 had much more discrepant values derived from linear interpolation and curve 2 than from curve 1, and column 3 is included only to demonstrate this point. Selective exclusion of subjects with values above 8 umol for each method would be even more misleading as different subjects would be included for each method.
With any measurement having an upper limit above which values cannot be obtained there is no ideal solution to the problem of estimating repeatability.
Methods can be properly compared only when carried out on the same or comparable subjects, and even then care must be taken not to exclude subjects more variable by one method than another. There is also the problem of whether the between subject variation used in the calculation of the intraclass correlation coefficient should be estimated from subjects tested twice or from a sample more representative of the population. PD1o had a greater within subject variation and greater between subject variation than PD20 in the 90 subjects; the intraclass correlation coefficient showed PD0o to be relatively less repeatable than Chinn, Britton, Burney, Tattersfield, Papacosta PD20. Judged against variation in all 793 subjects studied, PD0o and PD20 had similar repeatability. We have preferred to use PD20 since this has been used more often by others.
Other measures of reactivity that have been used elsewhere include threshold dose,16 which has been shown to be less repeatable"7 than PD20 and to add little information.
Most subjects (75%) increased their FEV, after the post-saline measurement. In most the increase was less than 100 ml, which is within the 200 ml 95% range that would be expected in subjects unfamiliar with a spirometer.'7 If we assume that the highest value is closer to the true FEV, it is appropriate to take the maximum FEV1 as a baseline rather than the postsaline FEV1. This decision is supported by the slightly smaller intraclass correlation coefficient of the maximum FEV1 than of the post-saline FEV1 (table 3) .
The difference, however, between the results from the two methods is trivial, the PD20 derived from the maximum FEV1 being on average only 0 008 log ,mol (equivalent to 0 03 doubling doses) less than that derived from the post-saline FEV1 (standard deviation of differences 0-036 log ,imol).
The repeatability of PD20 in this study, as estimated from curve 1, was similar to that found in laboratory based studies. Dehaut et all8 reported a 95% single determination "confidence interval" (strictly speaking a range, not a confidence interval) of 1 59 doubling concentrations; our within subject standard deviation of 0 27 gives a corresponding figure of 1 79 doubling doses. When our calculation was restricted to data tested under conditions more like those that would be imposed in a laboratory setting the within subject standard deviation was 0-18, equivalent to a 95% single determination interval of 12 doubling doses. Other laboratory studies have found better agreement than Dehaut between duplicate measurements, in trained and selected subjects; but these results should not be compared with our findings. An epidemiological study of a community population must include all respondents irrespective of technique if bias is to be avoided, and this will inevitably decrease repeatability of the method used.
Variability in FEY, makes linear interpolation from just two measurements unreliable and also reduces the number of estimates; the FEV1 at 4 smol can, by chance, be greater than the previous value; this renders linear extrapolation to a PD20 impossible whereas curve fitting will give an estimate. We did not obtain a direct estimate of the short term repeatability of FEVY, but the residual standard deviation about curve 1 was 0-15 1, well within the range of0-1-0 3 1 for different subgroups quoted by Tweeddale et all8 for repeat FEV, measurements in inexperienced subjects. Extrapolation using curve I increased the number of
